

30 July 2026

CARETEQ'S Q4 FY26 ACTIVITIES REPORT AND APPENDIX 4C

Balance sheet strengthened following EHS sale and capital raising; HMR Referrals strategic reset underway

Careteq Limited (ASX: CTQ) ("Careteq" or "the Company"), a clinical healthtech company delivering innovative and AI-enabled healthcare solutions, is pleased to provide the following quarterly update and commentary on its Appendix 4C for the quarter ending 30 June 2026.

Highlights

- ASX has confirmed continued quotation as announced on the 23rd July 2026.
- HMR Referrals strategic reset: The Company is now focused on executing on its growth plans for HMR Referrals which including staged AI-enablement and functionality and review of complimentary acquisition opportunities.
- Appointment of Mr Leonard Math as Non-Executive Director, a highly accomplished ASX director and executive.
- Strengthened the Company's balance sheet following the repayment of all outstanding loans and conversion of all convertible notes.
- Completion of Tranche 2 capital raising of \$2.07m which was strongly supported by new and existing shareholders.
- Strong cash balance at \$3.2m with no debts.
- Quarterly operating costs reduced to ~\$250k excluding one off costs.

Continued ASX Quotation

As announced on the 23rd July 2026, ASX has confirmed that the Company will continue quotation on the ASX following the divestment of Embedded Health Solutions Pty Ltd. The Company has sufficient operations and financial condition to warrant continued quotation of its securities on the ASX.

Strategic Reset

The June quarter was a transformational one for Careteq, with the Company completing the divestment of Embedded Health Solutions (EHS), receiving the proceeds from the two-tranche capital raising, repaying all borrowings, and ending the period with a materially strengthened cash position. The Company is now focused on the next phase of its operating strategy, centred on HMR Referrals and assessing complementary acquisition opportunities.

Operational Performance

Careteq closed the quarter with \$3.2m in cash, up from \$837,000 at the end of the previous quarter. The improved cash position reflects the net proceeds from the disposal of EHS, together with proceeds

from the capital raising, offset by operating cash outflows, transaction costs and the repayment of borrowings during the period.

As part of this transformation, Careteq has also substantially reduced its operating cost base to ~\$250k per quarter (~\$1m per year) excluding one off costs as compared to FY26 operating costs of \$8.2m.

Capital raising and balance sheet strengthening

During the quarter, Careteq completed Tranche 2 of the capital raising as announced in March 2026 via the issue of 401,367,364 new shares, raising approximately \$2.07m before costs.

Convertible note conversion

As per ASX release on 4th June 2026, Mr. Antanas (Tony G) Guoga elected to convert all of his convertible notes into fully paid shares in Careteq at \$0.01 per share. The decision to convert reflects Mr Guoga's confidence in Careteq's strategic direction and underscores the long-term alignment between one of Europe's most prominent technology investors and the Company's continued growth in clinical healthtech and AI-enabled healthcare delivery. Following the conversion, Careteq's capital structure has been materially simplified, with the Company having no convertible notes on issue and no drawn debt facilities.

HMR Referrals

The Board and management have commenced implementing our HMR Referrals strategic plan. The revised plan will focus on:

- GP Clinic activation
- Pharmacist recruitment
- AI capability scoping and build focused on process improvements
- Strategic collaborations with complementary industry partners
- Scale the platform to address unmet need in the home and aged care sector

As stated on our ASX release on the 23rd July 2026, each quarter, the company will report on its use of funds in relation to HMR Referrals as per the table below:

Focus Area	Estimate	Q4-FY26 Costs	Balance
GP Clinic Activation	185,000	12,500	172,500
Pharmacist Recruitment	140,000	12,600	127,400
AI Capability	140,000	7,500	132,500
Contingency	35,000	0	35,000
Total	500,000	32,600	467,400

The Company's objective is to position HMR Referrals as a focused, scalable and progressively technology-enabled platform in the home medication review sector while maintaining disciplined overhead management and preserving balance sheet flexibility.

ATO position update

Formal objection process ongoing with additional evidence submitted including key staff witness statements now sitting with the ATO's Objection Officer for their review and feedback. The Board will keep shareholders and the market informed as appropriate.

ASX Listing Rule 4.7C.3

In accordance with ASX Listing Rule 4.7C.3, payments to related parties and their associates totalling \$61k outlined in Item 6 of the Company's Appendix 4C relate to director fees, salaries, and superannuation.

This ASX announcement has been authorised by the Board of Careteq Limited (ASX: CTQ)**For further information, please contact:****Careteq Limited (ASX: CTQ)**

Mark Simari
Executive Chairman
E: info@careteq.com.au

About Careteq Limited (ASX: CTQ)

Careteq Limited (ASX: CTQ) is an Australian healthtech company focused on innovative solutions for the home care and disability sector. The Company is dedicated to improving healthcare outcomes through its fully owned marketplace platform, HMR Referrals which streamlines the process of completing Home Medicines Reviews (HMRs).

To learn more, please visit: www.careteq.com.au/

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Careteq's beliefs, assumptions, and expectations and on information currently available to Careteq. All statements that address operating performance, events or developments that Careteq or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Careteq or the market it operates in.

Careteq believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Careteq does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Careteq or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information

Follow us on [LinkedIn](#)

To learn more about Careteq please click here: <https://www.careteq.com.au/investors-centre/>

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Careteq Limited

ABN

83 612 267 857

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	765	6,978
1.2 Payments for		
(a) research and development	(33)	-
(b) product manufacturing and operating costs	(2)	(116)
(c) advertising and marketing	(2)	(39)
(d) leased assets	-	-
(e) staff costs	(839)	(5,796)
(f) administration and corporate costs	(797)	(2,245)
1.3 Dividends received	-	-
1.4 Interest received	6	9
1.5 Interest and other costs of finance paid	(319)	(342)
1.6 Income taxes paid	-	(24)
1.7 Government grants and tax incentives	-	5
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(1,221)	(1,570)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(20)	(83)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	—	—
	(b) businesses	4,003	4,003
	(c) property, plant and equipment	—	—
	(d) investments	—	—
	(e) intellectual property	—	—
	(f) other non-current assets	—	—
2.3	Cash flows from loans to other entities	—	—
2.4	Dividends received (see note 3)	—	—
2.5	Other (provide details if material)	—	—
2.6	Net cash from / (used in) investing activities	3,983	3,920

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,982	2,175
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	—	—
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(132)	(150)
3.5	Proceeds from borrowings	—	47
3.6	Repayment of borrowings	(2,272)	(2,272)
3.7	Transaction costs related to loans and borrowings	—	—
3.8	Dividends paid (Note 3)	—	—
3.9	Other (provide details if material)	—	—
3.10	Net cash from / (used in) financing activities	(422)	(200)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	837	1,027
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,221)	(1,570)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	3,983	3,920

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(422)	(200)
4.5	Effect of movement in exchange rates on cash held	—	—
4.6	Cash and cash equivalents at end of period	3,177	3,177

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,177	837
5.2	Call deposits	—	—
5.3	Bank overdrafts	—	—
5.4	Other (provide details)	—	—
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,177	837

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	61
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	—	—
7.2	Credit standby arrangements	—	—
7.3	Other (Convertible Note)	—	—
7.4	Total financing facilities	—	—
7.5	Unused financing facilities available at quarter end		0
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,221)
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,177
8.3	Unused finance facilities available at quarter end (item 7.5)	—
8.4	Total available funding (item 8.2 + item 8.3)	3,177
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1) <i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	2.60
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer:	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer:	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer:	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:30th July 2026.....

Authorised by:By the Board of Directors of Careteq Limited.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends paid may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.